Pharmaceutical Product Registration in Saudi Arabia

The SFDA requires all drug, health, herbal, and veterinary manufacturers to hold mandatory GMP licensing, which includes a physical site inspection by SFDA inspectors and payment of inspection fees. Foreign pharmaceutical companies must appoint a Saudi Authorized Representative (SAR) for Regulatory submissions and register with the Drug Establishments National Registry (DENR) to obtain login credentials for SFDA's electronic systems.

SFDA requires applications in the electronic Common Technical Document (eCTD) format, aligning with ICH standards. Applicants should expect multiple waves of inquiries (RFIs) throughout the process, particularly regarding the API section 3.2.S, stability studies, clinical trials, bioequivalence, labeling (PIL/SPC), pharmacovigilance system, and QPPV.

SFDA became the first Arab country admitted to the Pharmaceutical Inspection Co-operation Scheme (PIC/S), which harmonizes GMP inspection standards across 54 Regulatory authorities worldwide. On reliance pathways, SFDA engages in reliance mechanisms, reviewing decisions from regulators such as the US FDA and EMA to accelerate local approvals, while maintaining Saudi-specific safety and cultural considerations. The last version of the submission guidance added criteria for both first generics and biosimilars qualifying for priority review designation, with the priority review process for the first generic intended for the product considered the first generic to an innovative product already registered at SFDA.

Timelines typically range from 12–18 months for NDAs, with accelerated reviews available for priority medicines addressing urgent health needs. Requirements include GMP certification, laboratory testing, stability studies, and often pricing assessment. The final approval usually results in a five-year registration certificate valid for renewal.

Not always. SFDA's Product Specific Bioequivalence Guidance assists the generic pharmaceutical industry in identifying the most appropriate methodology for conducting bioequivalence studies. It includes guidelines for more than 400 active substances across different dosage forms with the most appropriate bioequivalence study design. Since the establishment of SFDA's electronic recording system for bioequivalence trials in 2017, hundreds of trials have been reviewed based on the SFDA Guidelines for Bioequivalence and the Product Specific Bioequivalence Guidance. Of 590 bioequivalence trials reviewed, 521 successfully demonstrated bioequivalence. BCS-based waivers are available for qualifying products where the active substance meets SFDA's solubility and dissolution thresholds.

SFDA has strict labeling and packaging requirements that must be complied with during the product registration process. Once approved, the labeling information must not be altered even minimally to maintain product compliance and avoid shipment rejection or withdrawal from the market. All labeling and patient information must be provided in Arabic, and products must comply with halal requirements when applicable, especially for excipients of animal origin.

SFDA requires all international MAHs to develop and maintain a local pharmacovigilance system in Saudi Arabia, documented in a Pharmacovigilance Sub-System File (PSSF), in addition to the company's global PSMF. In 2024, the submission of Risk Minimization Measures (RMMs) and proof of their efficacy in distribution became increasingly requested. The local QPPV must be licensed by the Saudi Commission for Health Specialties (SCFHS) and have experience or access to expertise in medicine, pharmaceutical science, epidemiology, and biostatistics.

Minor variations of "Type IB" must be submitted to SFDA before implementation, but do not require formal approval; however, the MAH should wait to implement the change to ensure the application is deemed acceptable. Major variations of "Type II", which may have a significant impact on the quality, safety, and efficacy of a medicinal product, require prior approval before implementation. A variation application is a post-approval Regulatory procedure that frequently takes place after SFDA drug registration to ensure that amendments to the registered drug file are approved for marketing. SFDA started charging for variation submission in 2021.

All non-commercial activities are the responsibility of the scientific office, including compliance with Regulatory requirements, pharmacovigilance, drug promotion, stock reporting, shortage of drugs, labeling updates, meeting and lecture approvals, medical representatives' licenses, and training of pharmacists. The technical director must be a full-time Saudi pharmacist licensed to practice the profession. A valid SFDA license for the scientific office and a valid SCFHS license for pharmacists are mandatory compliance requirements.

SFDA conducts GCP inspections to safeguard clinical trial integrity and protect the rights, safety, and welfare of study participants, ensuring trials are conducted in compliance with GCP and applicable laws. A total of 131 GCP inspections were performed between 2017 and 2023, generating 722 observations from 116 inspection visits. SFDA conducts inspection visits to clinical trial sites, bioequivalence centers, and monitoring facilities to ensure adherence to GCP standards, and has signed MoUs with hospitals and research centers, leading to a 40% increase in clinical trials in 2024.